NURPF Stock Price, Chart, Stats & News
Neuren Pharmaceuticals Limited (NURPF) is a dividend-paying stock with a current dividend yield of 0.73% as of Oct 20, 2026. It pays $0.1042 per share over the trailing twelve months and distributes annually.
Dividend safety
NURPF pays out about 99% of earnings, leaving little safety margin.
NURPF chart
About
Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes.
Related lists
Similar securities
Based on sector and market capitalization
